This exciting acquisition adds considerable expertise for a full complement of therapeutic specialization across our expanding global network.
Doylestown, PA (PRWEB) July 25, 2016
Bioclinica®, a provider of specialized technology-enabled services supporting clinical trials, today announced it has acquired Compass Research, a leading U.S. clinical research site network with direct access to a number of specialized populations with neurodegenerative disorders and other diseases found in aging demographics.
The acquisition solidifies Bioclinica’s position as a premier global research network—and the only one with investigator sites in the U.S., Europe, Latin America, and Asia.
Bioclinica President and CEO John Hubbard, Ph.D. said, “This exciting acquisition brings established, highly successful U.S. investigational sites into our global research network. The Compass Research team has built a strong operation that will set the model for our clinical research expansion in the United States.” He added, “With its industry reputation for being both patient-focused and the ‘go-to site’ for Alzheimer’s research, Compass will be a key part of our global research network.”
Headquartered in Orlando, Florida, Compass Research brings to Bioclinica state-of-the-art facilities and experienced clinicians focused on patient care. As a group, Compass researchers have supported more than 1,300 trials and contributed to the FDA approval of more than 80 biopharmaceutical products.
Compass Chief Medical Officer and co-founder Craig Curtis, MD, CPI said, “Compass Research has one of the most experienced Phase 1-4 site teams in the U.S and is a preferred provider for many of the largest biopharmaceutical companies globally.”
Most notably, Compass has an established presence in The Villages, the largest retirement community in the U.S. and home to 179,000 elderly residents who may contribute to research such as Arthritis, back, knee and hip pain, Women’s Health, Alzheimer’s Disease, dementia, as well as Type II Diabetes and cardiovascular diseases. The company also has a database of nearly 80,000 potential subjects amassed through a network of physicians and affiliate practices with in-clinic recruiters, as well as an in-house marketing and call center.
Compass Research CEO and co-founder Sean Stanton said, “Undoubtedly, access to patients combined with exceptional patient care have contributed to our industry-leading reputation. Our highly successful model is complementary to Bioclinica’s global network, and we feel confident in our ability to replicate it in other geographies as we add more sites across the country.”
The Compass leadership team will play a strategic role in the Bioclinica Research Network expansion. In addition to Mr. Stanton and Dr. Curtis, Chief Operating Officer Jeff Pohlig, and Compass Primary Investigators will assume key roles in the ongoing development of Bioclinica’s U.S. site network.
Bioclinica Global Clinical Research President Elizabeth Thiele said, “We are pleased to welcome this high-caliber management team and Compass colleagues to Bioclinica. These talented individuals will help steer our Research Network toward accelerated clinical development in Alzheimer’, Neurosciences, Cardiovascular, Osteoarthritis, Osteoporosis, Rheumatoid Arthritis, Pain, Vaccine, Migraine and other indications in which we are already working.”
Dr. Hubbard added, “This exciting acquisition adds considerable expertise for a full complement of therapeutic specialization across our expanding global network. In addition to the Research Network, we see unique synergies with our Medical Imaging, Biomarkers, eHealth Solutions, and Patient Recruitment-Retention teams to give our clients added insights to further their clinical development in a more efficient and cost-effective way.”
To introduce the latest addition to the expanding Bioclinica network, Bioclinica will exhibit with members of the Compass Research team at the Alzheimer’s Association International Conference (AAIC), a global forum to advance dementia science, in Toronto, Canada on July 24-28.
About Compass Research
Compass Research is a clinical research company dedicated to testing investigational medications that cover a broad range of diseases and disorders. By participating in a clinical research study with Compass Research, participants are given the opportunity to provide valuable information for the future of medicine. Our core value is to exceed the expectations of both our patients and sponsors. We do this through comprehensive quality control and attention to detail. Our staff has over 400 years of combined clinical research experience in all fields of medicine. This gives us extensive knowledge of the clinical research study process from beginning to end and the ability to provide quality data to our sponsors.
Bioclinica is a specialty services provider that utilizes expertise and technology to create clarity in the clinical trial process. Bioclinica is organized by three business segments to deliver focused service supporting multifaceted technologies. The Medical Imaging and Biomarkers segment provides medical imaging and cardiac safety services and includes a molecular marker laboratory. The eHealth Solutions segment comprises the eClinical Solutions platform; Clinverse Financial Lifecycle Solutions; Safety and Regulatory Solutions; Strategic Consulting Services; App xChange Alliances; and eHealth Cloud Services. Under the Global Clinical Research segment, Bioclinica offers a network of research sites, patient recruitment-retention services, and a post-approval research division. The Company serves more than 400 pharmaceutical, biotechnology and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. Learn more at http://www.bioclinica.com.